Asset profile

Tipranavir · Aptivus

Small molecule

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

How the evidence outlook works ↗

Competitive landscape

60 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 58 same-indication.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tipranavir (Aptivus): this drugApprovedSmall moleculeHIV protease
Darunavir (Prezista)ApprovedSmall moleculeHIV protease
Fosamprenavir (Lexiva / Telzir)ApprovedSmall moleculeHIV protease
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integrase
Cabotegravir (Vocabria / Cabenuva / Apretude)ApprovedSmall moleculeHIV integrase
Crofelemer (Mytesi)ApprovedSmall moleculeChloride channel (intestinal epithelium)
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integrase
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptase
Elsulfavirine (Elpida)ApprovedSmall moleculeHIV reverse transcriptase
Elvitegravir (Stribild / Genvoya (component))ApprovedSmall moleculeHIV integrase
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptase
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptase
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120
Ibalizumab (Trogarzo)ApprovedMonoclonal antibodyCD4 receptor
Lenacapavir (Sunlenca / Yeztugo)ApprovedSmall moleculeHIV capsid
Maraviroc (Selzentry / Celsentri)ApprovedSmall moleculeCCR5 co-receptor

…and 45 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

No upcoming readouts on record for this asset.

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 3 (7)
Phase 2/3 (1)
Phase 2 (8)
Phase 1/2 (2)
Phase 1 (32)
Phase 4 (2)
Early phase / not applicable (1)
Appears in other studies (2)